Logo
x

Search

Subscribe Now

Merck

Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers

Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers

  • October 24, 2024
Merck and Gilead Highlight the P-II Study Data of Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV at IDWeek 2024

Merck and Gilead Highlight the P-II Study Data of Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV at IDWee...

  • October 21, 2024
Merck Highlights the P-IIb/III (MK-1654-004) Study Data of Clesrovimab to Prevent RSV Disease in Healthy Preterm and Full-term Infantsat IDWeek 2024

Merck Highlights the P-IIb/III (MK-1654-004) Study Data of Clesrovimab to Prevent RSV Disease in Healthy Preterm and Full-term Inf...

  • October 18, 2024
Merck Provides Update on P-III (KEYNOTE-689) Study of Keytruda as a Perioperative Treatment of Head and Neck Squamous Cell Carcinoma

Merck Provides Update on P-III (KEYNOTE-689) Study of Keytruda as a Perioperative Treatment of Head and Neck Squamous Cell Carcino...

  • October 9, 2024
Merck Reports the CHMP’s Positive Opinions of Keytruda Regimens for Treating Indications of Gynecologic Cancers

Merck Reports the CHMP’s Positive Opinions of Keytruda Regimens for Treating Indications of Gynecologic Cancers

  • September 23, 2024
Merck Reports the US FDA’s Approval of Keytruda Plus Pemetrexed and Platinum Chemotherapy to Treat Malignant Pleural Mesothelioma (MPM)

Merck Reports the US FDA’s Approval of Keytruda Plus Pemetrexed and Platinum Chemotherapy to Treat Malignant Pleural Mesothelioma...

  • September 18, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.